The U.S. Food and Drug Administration (FDA) recently approved a monkeypox vaccine called ACAM2000, which is known to cause heart inflammation in about 1 in every 175 persons.
The vaccine, developed by Emergent BioSolutions, is intended for individuals at high risk for monkeypox infection. However, the FDA's own medication guide for the product suggests that the risks of the vaccine outweigh the benefits.
The vaccine can shed from the vaccination site and spread to other parts of the body or other people, causing serious complications. Side effects of ACAM2000 include heart inflammation, brain or spinal cord swelling, infection at the vaccination site, accidental eye infection, and fetal death in pregnant women.
The vaccine also contains a live vaccinia virus that can be spread to non-vaccinated individuals.
Experts and critics have expressed concern over the high risk and potential dangers associated with the ACAM2000 vaccine. The FDA emphasizes the importance of providing a medication guide to inform vaccine recipients of the serious risks involved.
However, it remains unclear how helpful the guide would be, as the vaccine is primarily intended for individuals engaging in risky, promiscuous, and unprotected sex.
